[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574898":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":43,"responsibleParty":62,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":26,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"King Edward Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Atorvastatin","ACTIVE_COMPARATOR","Atorvatstain 40mg OD",[13],"Drug: Atorvastatin 40 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Rosuvastatin","EXPERIMENTAL","Rosuvastatin 20mg",[19],"Drug: Rosuvastatin 20 mg\u002Fday",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rosuvastatin 20 mg\u002Fday","Rosuvastatin 20 mg \u002F Day for 24 weeks",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Atorvastatin 40 mg","Atorvastatin 40mg \u002F Day for 24 weeks",[9],[32,35],{"name":33,"affiliation":5,"role":34},"Uzma Malik","STUDY_CHAIR",{"name":36,"affiliation":5,"role":37},"Ali Hussnain","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":26,"email":42},"CONTACT","+923317641096","ahshah12@hotmail.com",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Lahore","Punjab Province","54000","Pakistan","PK",{"type":52,"coordinates":53},"Point",[54,55],74.35071,31.558,{"lat":55,"lon":54},[58],{"name":59,"role":40,"phone":60,"phoneExt":26,"email":61},"AP Endocrinology","+923004683473","sidrah.lodhi@gmail.com",{"type":37,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Sidrah Lodhi","Assistant Professor of Endocrinology","100574898","phase-4-impact-of-atorvastatin-versus-rosuvastatin-on-25-hydroxy-vitamin-d-levels-in-patients-with-acute-coronary-syndrome-100574898",false,"NCT06765265","Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\nAcute Coronary Syndrome\n\n25 OH-Vitamin D levels between 30-70ng\u002Fml\n\nExclusion Criteria:\n\nHypercalcemia\n\nhypocalcemia\n\npregnancy\n\nlactation\n\nhypersensitivity to statins\n\nhypothyroidism\n\nDeranged LFTs \\& RFTs\n\nUse of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)","ALL","18 Years","65 Years",{"count":75,"type":76},152,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months",[82],"Acute Coronary Syndromes",[84,85,86,87,88],"atorvastatin","rosuvastatin","Vitamin D","Triglyceride","Lipid Profile","2025-03-07",{"date":91,"type":92},"2025-03-11","ACTUAL",{"date":94,"type":92},"2025-01-05",{"date":96,"type":76},"2026-01-01",{"name":5,"class":6},1]